The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. We prepared seven + (L1 ) (2-pyridylmethyl) 2 N(CH 2 ) 4 CH(CO 2 H)-NHCO-(CH 2 ) 6 CO-NH-lys-NHCONH-glu) showed the highest, most selective PIP tumor uptake, at 7.9 ( 4.0% injected dose per gram of tissue at 30 min postinjection. Radioactivity cleared from nontarget tissues to produce a PIP to flu (PSMA-PC3) ratio of 44:1 at 120 min postinjection. PSMA can accommodate the steric requirements of 99m Tc/Re complexes within PSMA inhibitors, the best results achieved with a linker moiety between the ε amine of the urea lysine and the chelator.
Introduction
Prostate cancer (PCa) is the leading cancer in the U.S. population and the second leading cause of cancer-related death in men. 1 By the time of diagnosis, only one-half of PCa tumors are clinically localized and one-half of those represent extracapsular spread. Currently anatomic methods, such as computed tomography (CT), magnetic resonance (MR) imaging, and ultrasound, predominate for clinical imaging of prostate cancer. The radiolabeled monoclonal antibody [
111 In]ProstaScint has also been used, however, this agent tends to produce images that are challenging to interpret. [2] [3] [4] Low-molecular-weight, radiopharmaceutical-based imaging agents may provide superior pharmacokinetics for imaging than radiolabeled antibodies, which tend to have long circulation times and delayed clearance from nontarget tissues. A variety of experimental low-molecularweight PCa imaging agents are currently being pursued clinically, including radiolabeled choline analogues, 5- 12 Each operates by a different mechanism and has certain advantages, e.g., low urinary excretion for [ 11 C]choline, and disadvantages, such as the short physical half-life of positron-emitting radionuclides. A promising new series of low-molecular-weight imaging agents targets the prostate-specific membrane antigen (PSMA). [13] [14] [15] [16] PSMA is a type II integral membrane protein that has abundant and restricted expression on the surface of PCa, particularly in androgen-independent, advanced, and metastatic disease. 17 The latter is important because almost all PCa becomes androgen independent. It is also expressed within the endothelium of most solid tumors other than prostate. 18 PSMA possesses the criteria of a promising target for therapy, i.e., abundant and restricted (to prostate) expression at all stages of the disease, presentation at the cell surface but not shed into the circulation, and association with enzymatic or signaling activity. 17 The PSMA gene is located on the short arm of chromosome 11 and functions both as a folate hydrolase and neuropeptidase. It is the neuropeptidase function that is equivalent to glutamate carboxypeptidase II (GCPII), which is referred to as the "brain PSMA", 17 and may modulate glutamatergic transmission by cleaving N-acetylaspartylglutamate (NAAG) to N-acetylaspartate (NAA) and glutamate. 19 There are up to 10 6 PSMA molecules per cancer cell, further suggesting it as an ideal target for imaging and therapy with radionuclide-based techniques.
oyl]-(S)-3-[
125 I]iodo-L-tyrosine, [
I]DCIT, and N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-(S)-4-[
18 F]fluorobenzyl-Lcysteine, [ 18 F]DCFBC (Chart 1). [13] [14] [15] These results encouraged us to investigate the possibility of developing 99m Tc-labeled, urea-based inhibitors as PCa imaging agents. Although positronemitting radionuclides are increasingly used in clinical medicine, 99m Tc remains the radionuclide of choice for clinical scintigraphic imaging because of its favorable physical properties (t 1/2 ) 6 h, E γ ) 140 keV), low cost, and widespread availability. The development of technetium complexes as radiopharmaceuticals is facilitated by the use of rhenium, the group VIIB congener of technetium. Rhenium generally produces complexes with similar physical properties to those of technetium and is often used as a nonradioactive alternative to technetium for large-scale synthesis and structural characterization.
Here we describe the development of low-molecular-weight, urea-based inhibitors incorporating tridentate chelators for binding of the {M(CO) 3 } + core, (M ) 99m Tc, 186,188 Re), while retaining high affinity to PSMA. Because of high stability and favorable labeling characteristics, the organometallic Re(I)(CO) 3 / 99m Tc(I)(CO) 3 approach represents an attractive radiolabeling strategy. A number of tridentate chelates with different sets of nitrogen, sulfur, oxygen donor atoms are known to form highly stable complexes with the {M(CO) 3 } + cores. 21, 22 Among them, the single amino acid chelate concept, 23, 24 (SAAC), has proved useful for designing our new urea-based inhibitors. We describe the synthesis and in vitro binding of seven 99m Tc/Re-based radiopharmaceuticals formed from ligands L1-L7 (Chart 2) as well as ex vivo biodistribution and in vivo imaging studies of selected agents.
Chemistry
Structure-Based Design of PSMA Binding Inhibitors. Recently, several high-resolution X-ray crystal structures of GCPII (PSMA) with known, low-molecular-weight, glutamatecontaining inhibitors of PSMA have been reported. [25] [26] [27] [28] Those structural studies established that the binding site of PSMA contains a binuclear zinc ion and two substrate binding pockets, i.e., an S1 (nonpharmacophore) pocket and an S1′ (pharmacophore) pocket. The active site also contains a chloride ion in the S1 pocket. In the vicinity of the S1 pocket resides a funnelshaped tunnel with a depth of approximately 20 Å and a width of 8-9 Å. 25 Similarly, a narrow cavity is present near the S1′ pocket. 27 Moreover, it has been determined that the glutamate moiety of the inhibitors has a predisposition to orient within the narrow S1′ pocket, whereas the remainder of the molecule resides within the large S1 pocket. These observations are similar for PSMA X-ray crystal structures upon cocrystallization with compounds in the urea series, namely, DCMC, DCIT, and DCFBC (Chart 1) (data not shown). In the current study, we sought to synthesize a conjugate between a glutamate-containing, urea-based inhibitor and known chelators of [Re(I)(CO) 3 ] + /[ 99m Tc(I)(CO) 3 ] + . In the design of these new conjugates, it was important to optimize the interaction between PSMA and the bulky chelator. Considering the ∼9 Å diameter of the rhenium tricarbonyl and technetium tricarbonyl coordination spheres with pyridyl-based chelates, determined from reported X-ray crystal structures, 29, 30 the calculated average volume of the metal tricarbonyl core with the bispyridyl chelate was found to be ∼378 Å 3 . To enable high-affinity binding of our putative imaging agents to PSMA, we envisioned the need to attach a functionalized methylene linker (>20 Å) to the remainder of the molecule from the R-carbon of the urea function. Accordingly, we have designed three sets of compounds, each with a different linker length: L1-L3, with a linker of ∼31.5 Å, L4 and L7, with linker length of ∼33 Å, and L5 and L6, with linker lengths of ∼22 Å and 7.7 Å, respectively (Chart 2). We hypothesized that the metal chelate portion of the compound should remain outside of the 20 Å tunnel as long as the
glutamate moiety is maintained within the S1′ pocket, permitting interaction between the inhibitor and PSMA.
Synthesis of Urea-linked Chelators. We elected to develop a new series of PSMA inhibitors containing lysine (Chart 1, DCL) in order to utilize the free ε amine of lysine for conjugation or derivatization with a suitable metal chelating group. Compound 1 (Scheme 1) is a key intermediate, integral to synthesis of all of the putative imaging agents described. The protected lysine analogue 2 was prepared in two steps. Commercially available N ε -Boc-N R -Fmoc-L-lysine was reacted with 4-methoxybenzyl chloride and cesium carbonate in N, Ndimethylformamide (DMF), followed by removal of the Fmoc group using 20% piperidine in DMF. Flash chromatography provided the desired compound 2 in 80% yield. Urea 3 was obtained by treating bis-4-methoxybenzyl-L-glutamate · HCl, 4 31, 32 with triphosgene and triethylamine at -78°C followed by in situ trapping of the isocyanate intermediate by addition of 2. Selective cleavage of the N-Boc group of 3 with p-toluenesulfonic acid in ethanol/ethyl acetate 33,34 produced 5. Basic extraction of a solution of 5 in CH 2 Cl 2 gave the free base 1. The p-methoxybenzyl (PMB) group was conveniently removed at room temperature by using trifluoroacetic acid (TFA)/anisole or TFA/CH 2 Cl 2 solution in the final step after performing the required conjugation.
The synthesis of the chelators and their conjugation with intermediate 1 are presented in Schemes 2-6. Compound 1 was used to attach different linkers as well as metal chelators to generate a new series of PSMA inhibitors, L1-L7, for coordination of { 99m Tc(CO) 3 } + /{Re(CO) 3 } + . Key N-hydroxysuccinimide (NHS) ester intermediate 6, shown in Scheme 2, was prepared by conjugation of 1 with excess disuccinimidyl suberate (DSS) in DMF. Compound 6 was then reacted with three different bispyridyl chelators, 7, 9, and 13, a bisquinoline chelator, 8, and a monopyridyl monoacid chelator, 11, to prepare L1-L4, and L7. Chelators 7, 8, 9, and 13 were prepared according to published procedures. 35 Synthesis of the monopyridyl monoacid chelator was performed by modification of a previously described procedure (Scheme 3). Compound 10 was prepared according to a previously reported method. 36 Reductive amination of 10, using glyoxylic acid in presence of sodium triacetoxyborohydride in dichloroethane, followed by removal of the protecting group using a solution of TFA/CH 2 Cl 2 at ambient temperature, produced 11. The synthesis of L5 is outlined in Scheme 4. Compound 12 was prepared by reductive amination of commercially available 8-aminocaproic acid with pyridine-2-carboxaldehyde and sodium triacetoxyborohydride followed by NHS ester formation with N-hydroxysuccinimide in the presence of O-benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluorophosphate (HBTU). Compound L5 was obtained by reacting 12 with 5 in CH 2 Cl 2 and triethylamine, followed by deprotection of the PMB groups using TFA/CH 2 Cl 2 . Compound L6 was prepared by reductive amination of 1 using pyridine-2-carboxaldehyde and sodium triacetoxyborohydride followed by deprotection of the PMB groups using TFA/CH 2 Cl 2 (Scheme 5).
Synthesis of Rhenium Analogs (ReL1-ReL7). Synthesis of compounds [Re(CO) 3 
L]
+/0 (L ) L1-L7) was performed by ligand exchange reaction using the rhenium tricarbonyl precursor [Re(CO) 3 (H 2 O) 3 ]Br 37 as shown in Scheme 6 for L1. Equimolar quantities of the ligand (L1-L7) and the precursor were refluxed under argon for 3 h to afford the corresponding rhenium complex in quantitative yield in each case. The complexation was monitored by high-performance liquid chromatography (HPLC). All complexes were purified via HPLC and characterized by standard spectroscopic methods.
Modeling of L1 in the Active Site of PSMA. For molecular modeling studies of L1 with PSMA, a recently published crystal structure of PSMA in complex with (S)-2-(4-iodobenzylphosphonomethyl)-pentanedioic acid (GPI-18431) (PDB ID: 2C6C) was used. 25 Initially, we carried out docking studies of L1 with the active site of 2C6C using LigandFit and CHARMm-based CDOCKER protocols implemented in Discovery Studio 1.7 (DS 1.7, Accelrys Inc.). However, none of them produced docked poses in the active site because of the bulkiness of L1. Therefore, we employed an alternative way to elucidate a potential binding mode of L1. PSMA crystal structures with several ligands including GPI-18431, 2-(phosphonomethyl)pentanedioic acid (2-PMPA) and glutamate showed that the glutamate portion of these compounds within the S1′-pocket virtually overlap, suggesting that the orientation of the glutamate moiety is unchanged despite a variety of structural motifs concurrently within the S1-pocket. That was no surprise, as we expected the glutamate portion of L1 to orient in the S1′-pocket in a fashion similar to that of the known PSMA inhibitors (e.g., GPI-18431 and 2-PMPA). In particular, the R-carboxylate of glutamate, which interacts with Arg 210, is known to be essential for PSMA binding. 38 We superimposed L1 with GPI-18431 using four tether attachment points in glutamate (N-CH(COO -)-CH 2 , see Supporting Information, Figure 1) . Coordinates of the superimposed L1 were transferred and merged in the apo-form of 2C6C in which the ligand GPI-18431 was removed.
Molecular dynamics simulation of the merged PSMA/L1 complex was performed with Generalized Born with a simple Switching (GBSW) as an implicit solvent model. Amino acid residues within 7 Å of L1 remained flexible while all other amino acids were constrained. As shown in Supporting Information Figure 2 (see Supporting Information), the location of the carboxylic acid in the lysine portion of L1 dramatically changed and strongly interacted with two arginines (Arg 534 and Arg 536, Figure 1A ) after molecular dynamics simulation, while the two carboxylic acids of glutamate changed only slightly. The linear-type linker of initial L1 was grooved for maximizing interaction with the tunnel region of PSMA, i.e., the flexible linear-type linker of initial L1 adopted a compact conformation, thus enhancing the interaction of L1 with the tunnel region of PSMA after molecular dynamics simulations ( Figure 1B and Supporting Information Figure 2 3 } + core complexes. Consequently, the fluorescent properties of ReL2 were investigated to determine whether the rhenium-based complexes possess suitable characteristics for use as biological probes. 39, 40 The electronic spectrum of ReL2 exhibited absorbance at 321 nm with an extinction coefficient of 17200 M -1 . Excitation of ReL2 at 321 nm provides an intense fluorescence emission at 550 nm. The large Stokes shift is characteristic of this class of fluorophore. 41 The emission peak is assigned to a 
41-44
The fluorescence lifetime for ReL2 is 11.8 µs (λ em ) 550 nm) in ethylene glycol under an argon atmosphere, which is sufficiently long to overcome the effects of endogenous fluorescence. Cellular autofluorescence can complicate in vitro imaging studies, however, because it occurs on the nanosecond time scale, it can be eliminated using time-gating techniques so long as the probe under investigation has a sufficiently long lifetime. The fluorescence quantum yield of ReL2 of 0.018 in ethylene glycol under argon is low but comparable to those reported for other transition-metal band fluorescence probes.
44,45

Biological Results
In Vitro Binding Studies. The relative binding affinities of L1-L7 and ReL1-ReL7 were determined using the N-acetylated-R-linked acidic dipeptidase (NAALADase) assay as previously described. 46, 47 The data are presented in Table 1 , with corresponding structures shown in Chart 2. As all compounds possess the lys-NHCONH-glu motif, structural variation derives from (a) the length of the linker between the chelator and the amide carbonyl carbon attached to the lysine moiety, (b) the chelator, which may be either the bispyridyl, bisquinoline, or mixed (monopyridyl monocarboxyl) functional groups, (c) the presence or absence of a second amide function between the chelator and the first amidesattached to the lysine moiety, and (d) the presence or absence of a carboxyl group either adjacent to the chelator or adjacent to the second (linker) amide group. Immediately evident is the need for a methylene chain length longer than that provided by lysine itself, as the Re-chelated version of L6 displays the lowest PSMA inhibitory activity of all compounds measured and was not capable of imaging PMSA+ tumors (data not shown). Compound L5 demonstrates that linkers containing seven methylene units between the chelator nitrogen and the amide carbonyl provide compounds of low nanomolar K i . Longer linkers can also be accommodated easily (L4 and L7). Introduction of rhenium does not cause a consistent change in inhibitory activity with Re-labeled versions only of L1, L4, and L5, demonstrating higher inhibitory activities than the corresponding unchelated compounds. Introduction of the Re(CO) 3 core/moiety to chelators of this class forces the chelator into a facial configuration, with unpredictable effects on binding to the active site. Placing the carboxylate adjacent to the chelator (L3), rather than adjacent to the amide nitrogen on the linker (L1) caused an increase in inhibitory activity of over an order of magnitude for the unchelated versions, although the Re-labeled versions were comparable. The bisquinoline chelator, which is much less polar than the bispyridyl, provides correspondingly stronger PSMA inhibitory activity. Replacing one of the pyridines with a carboxylic acid moiety (L7 to L4) causes a 6-fold increase in inhibitory activity for the unchelated molecules but a 12-fold decrease in activity for the more biologically relevant Re-labeled compounds. Because of the many structural perturbations provided in this small structure-activity series, it is difficult to determine the effect of linker chain length other than to say that a linker beyond the lysine moiety itself is necessary for productive interaction with PSMA.
Ex Vivo Biodistribution. Compounds [ 99m Tc]L1-L3 were assessed for their pharmacokinetics ex vivo in severe-combined immunodeficient (SCID) mice bearing both PSMA+ PC3 PIP and PSMA-flu xenografts.
14,18 Tables 2-4 show the percent injected dose per gram (%ID/g) uptake values in selected organs for compounds [
99m Tc]L1-L3, respectively. Compound [ 99m Tc]L1 showed clear PSMA-dependent binding in PC3 PIP tumor xenografts, reaching a maximum uptake, among times investigated, of 7.87 ( 3.95%ID/g at 30 min postinjection (pi). PSMA+ tumor to PSMA-tumor (PIP:flu) uptake ratios ranged from 23 at 30 min pi to a high of 68 at 300 min pi. The distribution within normal organs and tissues was also favorable, with low nonspecific tissue uptake and rapid clearance. The highest nonspecific uptake observed was in the spleen at 30 min pi and was 10.59 ( 6.05%ID/g, which decreased to 1.81 ( 1.10 by 60 min pi. Kidney uptake, chiefly due to high expression of PSMA within proximal tubules, 48 was expectedly The remaining compounds of this series ([ 99m Tc]L4-L7) underwent imaging (see below), however, the images suggested that these compounds did not warrant further ex vivo analysis.
Metabolism. Except for mouse kidney extracted 60 min after injection of [ 99m Tc]L1, which contained 2% of its extracted radioactivity as a polar metabolite, all of the other tissue extracts, plasma, and urine at 30 and 60 min postinjection contained 100% of the chromatographed radioactivity as the parent compound.
Microscopy. Coordination of the bisquinoline moiety of L2 with Re(CO) 3 renders this complex fluorescent. Accordingly, we performed microscopy using ReL2 in live cells ( Figure 2 ). Because the Stokes shift for ReL2 is relatively large, it was necessary to excite at 494 nm and collect emission fluorescence at 628 nm. Efforts to excite at 321 nm, where the quantum efficiency for this ligand was expected to be highest, resulted in extreme autofluorescence and no useable data. Excitation in the green region of the spectrum, however, led to a weak but observable fluorescent signal from within the PSMA+ PC3 PIP cells. This result provides visual confirmation of internalization of low-molecular-weight ligands for PSMA. The mechanism of internalization of PSMA has been studied previously, however, only antibodies and antibody conjugates have been used rather than small molecules. 49, 50 Imaging. SPECT-CT imaging was carried out in SCID mice. Each mouse had a PSMA+ PC3 PIP and PSMA-PC3 flu xenograft in opposite, upper flanks. All radioligands were screened this way, and the results obtained were used to determine whether ex vivo biodistribution assay would add further information. As a further test of in vivo binding specificity, we performed a blocking study using [
99m Tc]L1 in an LNCaP (PSMA+) prostate tumor model but first pretreating the animal with 50 mg/kg of the potent, selective PSMA inhibitor, 2-(phosphonomethyl)pentanedioic acid (PMPA).
15,51 Figure 5 shows that PMPA is capable of eliminating binding of [ 99m Tc]L1 not only to tumor but also to the renal cortex, another site of specific binding for radiopharmaceuticals of this class. These results provide one more check on in vivo binding selectivity, using a blocking agent from a different chemical class than the ureabased inhibitors, and in a different, well-established, PSMA+ prostate tumor.
Discussion
Despite advances using a variety of imaging modalities, most notably MR spectroscopy, clinically viable molecular imaging of PCa has remained elusive. FDG-PET, which has worked so well not only for identification of primary and metastatic tumors but also for therapeutic monitoring, has largely failed in the case of PCa, perhaps due to the relatively low rate of metabolism of these tumors compared to other epithelial cancers. Although iterative reconstruction with anatomic coregistration can improve ProstaScint imaging 52 and using a radiolabeled version of the J591 human monoclonal antibody against an extracellular epitope of PSMA show some promise, 53 ,54 these agents will be fraught with the same disadvantages of all intact antibodies for imaging, namely slow clearance from blood and nonspecific sites. Nevertheless, these antibodies bind to what we consider an ideal target for prostate cancer imaging and therapys PSMA.
The radiopharmaceuticals we describe here are part of a series of new low-molecular-weight PSMA-based imaging agents. They are all based on ureas first described by Kozikowski et al., which are synthetically accessible, high-affinity inhibitors of PSMA. 55 We have previously demonstrated the specific binding of suitably functionalized ureas to PSMA for imaging with SPECT and PET. However, those agents were radiolabeled with either 125 I, 11 C, or 18 F. [13] [14] [15] Iodine-125-labeled agents can be used in conjunction with high-resolution small animal imaging devices to study experimental models and the isotope can be switched to 123 I or 124 I for human SPECT or PET, respectively. However, those isotopes are expensive ($1000/ mCi for [ 124 I]NaI) and can be difficult to obtain on short notice. Carbon-11 is largely an experimental radionuclide for use only at centers that have a cyclotron in-house. Fluorine-18-labeled radiopharmaceuticals can be shipped limited distances, but those compounds will be of relatively low specific radioactivity upon arrival at the site of usage. Fluorine-18 also requires a cyclotron for production. For these reasons, the ready availability (via generators delivered to nuclear medicine departments daily) and ideal imaging characteristics of 99m Tc, we have embarked on a program to synthesize 99m Tc-labeled PSMA-based imaging agents. We have found that using SAAC technology developed by one of us (SRB) 56 in collaboration with Molecular Insight Pharmaceuticals, Inc. (Cambridge, MA), 99m Tc can be readily incorporated in a sterically unobtrusive manner to these PSMAbinding ureas. Because Tc has no stable isotope, we used the group VIIB congener Re for the PSMA inhibitory studies.
We synthesized seven compounds, designated L1-L7, in both their Re-and 99m Tc-labeled forms. All seven compounds derive from DCL (Chart 1), with different linkers between the ε amine of lysine and the chelator. Using SAAC technology, three different chelators were generated, namely the bispyridyl, the bisquinoline, and monopyridyl-monoacid. The primary rationale for the use of these different chelators was to exploit their differing degrees of steric bulk and lipophilicity. Both L1 and L2 provide cationic complexes upon complexation with the organometallic 99m Tc(CO) 3 /Re(CO) 3 core. On the other hand, L4 offers a neutral complex for the metal tricarbonyl core. Compound L2 provides the most lipophilic agent (Table 1) Figure 3 ). PIP and flu tumors are derived from PC3 human prostate cancer cells that differ only in their expression of PSMA (PIP ) PSMA+, flu ) PSMA-). 14, 18 Another way to alter the lipophilicity of these complexes is to introduce a carboxylic acid moiety to various positions on the linker. Moving the linker carboxylic acid to the carbon adjacent to the chelator nitrogen caused the binding affinity to drop (ReL3) and provide lower PIP:flu and higher liver and spleen uptake than compound [
99m Tc]L1 (Figure 3 ). In this series of three compounds, [ 99m Tc]L1 is a promising clinical candidate because of its synthetic accessibility, very high target to nontarget ratio (PIP:flu ) 44:1 at 2 h postinjection), rapid washout kinetics, metabolic stability, and the many salutary characteristics of 99m Tc discussed above. The initial indication for its use would be to study patients who have undergone prostatectomy in whom a rising prostate-specific antigen (PSA) is detectedsthe same indication as for ProstaScint. Compound ReL2 has documented the internalization of PSMA after binding of a low-molecular-weight agent to the active site (Figure 2 ). This compound could be used to study the kinetics of PSMA internalization. The internalization of compounds of this class suggests the development of the corresponding radiotherapeutic analogs. Future studies will involve further alterations in linker length and lipophilicity in an effort to binding to liver and other nonspecific sites.
Experimental Section
General Procedures. All reactions were performed under a nitrogen atmosphere unless otherwise noted. Solvents and chemicals obtained from commercial sources were of analytical grade or better and used without further purification. All experiments were performed in duplicate or triplicate to ensure reproducibility. Analytical thin-layer chromatography (TLC) was performed using Aldrich aluminum-backed 0.2 mm silica gel Z19, 329-1 plates and visualized by ultraviolet light (254 nm), I 2 , and 1% ninhydrin in EtOH. Flash chromatography was performed using silica gel purchased from Bodman (Aston, PA), MP SiliTech 32-63 D 60 Å. In most cases, product isolation consisted of removing of the solvent from the reaction mixture, extracting with an organic solvent, washing with water and brine, drying with anhydrous sodium sulfate, filtering, and concentrating the filtrate. The use of such workup conditions will be indicated by the phrase "product isolation" (which is followed, in parentheses, by the extracting solvent). Purification in most cases was achieved by flash chromatography and is signified by the term "flash chromatography" (which is followed, in parentheses, by the elution solvent used). Melting points were measured using a Mel-Temp apparatus and are uncorrected. 1 H NMR spectra were recorded on either a Varian Mercury 400 MHz or on a Bruker Ultrashield 400 MHz spectrometer. Chemical shifts (δ) are reported in ppm downfield by reference to proton resonances resulting from incomplete deuteration of the NMR solvent. Low resolution ESI mass spectra were obtained on a Bruker Daltonics Esquire 3000 Plus spectrometer. Higherresolution FAB mass spectra were obtained on a JEOL JMS-AX505HA mass spectrometer in the mass spectrometer facility at the University of Notre Dame. Optical rotation was measured on a Jasco P-1010 polarimeter. Infrared spectra were obtained on a Bruker Tensor 27 spectrometer. High-performance liquid chromatography (HPLC) purification of L1-L7 and ReL1-ReL7 using a Phenomenex C 18 Luna 10 × 250 mm 2 column was performed on a Waters 600E Delta LC system with a Waters 486 tunable absorbance UV/vis detector, both controlled by Empower software. Purification of ReL1-L7 and [
99m Tc]L1-L7 by HPLC was performed using the following isocratic conditions: method 1, the mobile phase was 65% solvent A (0.1% TFA in water) and 35% solvent B (0.1% TFA in CH 3 CN), flow rate 2 mL/min; method 2, mobile phase was 65% solvent A and 35% solvent B, flow rate 4 mL/min; method 3, mobile phase was 70% solvent A and 30% solvent B, flow rate 2 mL/min. Eluant was monitored at 254 and 220 nm. For radiosynthetic purification, HPLC was performed with a Waters Chromatography Division HPLC system equipped with two model 510EF pumps, a model 680 automated gradient controller, a model 490 UV absorbance detector, and a Bioscan NaI scintillation detector connected to a Bioscan Flow-count system. The output from the UV detector and the Flow-count radiodetector system were fed into a Gateway 2000 P5-133 computer fitted with an IN/US System, Inc. computer card and analyzed using Winflow software (IN/US). Absorption spectra were collected using a Hewlett-Packard 8453 spectrophotometer. The Isolink kit was a generous gift from Mallinckrodt-Tyco Health Care (St. Louis, MO, USA).
2-Amino-6-tert-butoxycarbonylamino-hexanoic acid 4-methoxybenzyl ester (2). Compound 2 was prepared in two steps. Into a 250 mL, flame-dried three-necked round-bottom flask under nitrogen was placed N ε -Boc-N R -Fmoc-L-lysine (7.0 g, 15 mmol) and 60 mL of dry DMF. To this was added cesium carbonate (7 g, 21 mmol) and 4-methoxybenzyl chloride (2.5 g, 16 mmol). The suspension was stirred at room temperature under nitrogen for 4 h, then filtered and washed with ethyl acetate. Product isolation (EtOAc, 5% Na 2 CO 3 , water, Na 2 SO 4 ) followed by recrystallization from 60/40 (v/v) hexane/EtOAc gave 2 crops of a colorless solid. mp 118-120°C. TLC R f ) 0. 33 {3-[1-p-Methoxybenzylcarboxylate-(5-t-butylcarbamylpentyl)]-ureido}-di-p-methoxybenzyl pentanedioate (3) . Bis-4-methoxybenzyl-L-glutamate · HCl 4 (3.6 g, 8.5mmol ) 31, 32 was placed in a flamedried three-neck round-bottom flask under nitrogen and dissolved in 15 mL CH 2 Cl 2 . Triphosgene (0.833 g, 2.8 mmol) was placed in a vial, dissolved in 3 mL CH 2 Cl 2 and added to the three neck flask. The flask was cooled to -77°C (dry ice ethanol slurry) under nitrogen. To this was slowly added triethylamine (12 mL, 85 mmol in 10 mL CH 2 Cl 2 ). The reaction mixture was stirred at -77°C for 1 h, allowed to warm to room temperature and was stirred for 30 min at rt. To this was added compound 2 (3.1 g, 8.5 mmol in 7 mL CH 2 Cl 2 ). The resulting mixture was stirred overnight. Product isolation (CH 2 Cl 2 , water, NaCl, Na 2 SO 4 ) followed by flash chromatography (20/ 
2-
p-Toluenesulfonate salt of 2-{3-[1-p-methoxybenzylcarboxylate-(5-aminopentyl)]-ureido}-di-p-methoxybenzyl pentanedioate (5).
A solution of 3 (2 g, 2.6 mmol) dissolved in 20 mL EtOAc was cooled to 0-2°C in an ice bath and p-toluenesulfonic acid monohydrate (0.49 g, 2.6 mmol) in 5 mL of absolute ethanol was added. The cooling bath was removed, and the reaction mixture was allowed to warm to room temperature for 2 h. The reaction mixture was then concentrated to a thick oil under reduced pressure, and the mixture was purified with flash chromatography using 10/90 MeOH/ CH 2 Cl 2 to afford product as colorless solid in 45% (0.98 g, 1.15mmol) yield. TLC R f ) 0.47 (10/90 MeOH/CH 2 Cl 2 ). 
2-{3-[1-p-Methoxybenzylcarboxylate-(5-aminopentyl)]-ureido}-di-p-methoxybenzyl pentanedioate (1).
A solution of 5 (0.15 g, 0.17 mmol in 50 mL CH 2 Cl 2 ) was placed in a separatory funnel, washed with 100 mL of 0.5 M NaHCO 3 . The organic layer was collected, dried over anhydrous Na 2 SO 4 , filtered, and concentrated to a yellow film (0.107 g, 0.09 mmol, 52.5%). TLC R f ) 0.40 (10/90 MeOH/ CH 2 Cl 2 ). 
2-{3-[5-[7-(2,5-Dioxo-pyrrolidin-1-yloxycarbonyl)-heptanoylamino]-1-(4-methoxy-benzyloxycarbonyl)-pentyl]-ureido}-pentanedioic Acid Bis-(4-methoxy-benzyl) Ester (6).
A 100 mL round-bottom flask was flame-dried under N 2 , after which 1 (0.08 g, 0.12 mmol) was added and then dissolved in 10 mL of dry DMF. This solution was added dropwise to a solution of suberic acid bis-(N-hydroxysuccinimide ester), DSS (0.13 g, 0.35 mmol in 10 mL DMF), at room temperature with mild stirring. After 2 h, the volume of the solution was reduced under vacuum, and the colorless solid residue was kept under high vacuum for 2 h further to remove traces of DMF. The residue was dissolved in 1 mL of CH 2 Cl 2 and was loaded onto silica gel column (1 in. × 12 in. + . Compounds L1-L3 were prepared by following the same general synthetic procedure as shown in Scheme 2 for L1 as a representative case.
2-[3-(5-{7-[5-(Bis-pyridin-2-ylmethyl-amino)-1-carboxy-pentylcarbamoyl]-heptanoylamino}-1-carboxy-pentyl)-ureido]-pentanedioic Acid (L1).
A solution of 7 35 (0.035 g, 0.107 mmol in 0.5 mL MeOH) was added to a stirred solution of 6 (0.100 g, 0.107 mmol in 6 mL dry DMF) at room temperature followed by the addition of 0.2 mL NEt 3 . The reaction mixture was stirred for 10 h at room temperature. The reaction mixture was then concentrated under reduced pressure. Product isolation (CH 2 Cl 2, water, Na 2 SO 4 ) followed by flash chromatography ( (20 mg, 0 .017 mmol) was dissolved in an ice-cold solution of TFA (7 mL) and anisole (0.3 mL) and was stirred for 10 min. The ice bath was removed and the solution was allowed to warm to room temperature with continued stirring for another 10 min. The solution was evaporated under reduced pressure, and the light-brown residue was dried under high vacuum for 2 h. The residue was washed with diethyl ether (3 × 5 mL) and water (10 × 2 mL) to produce crude L1. Yield: 9 mg, 0.011 mmol, 65%. The colorless product was dried under vacuum and purified further by HPLC using 75/25 water (0.1% TFA)/acetonitrile (0.1%TFA) as mobile phase, flow rate 2 mL/min; R t ) 14 min. 
2-[3-(5-{7-[5-(Bis-pyridin-2-ylmethyl-amino)-5-carboxy-pentylcarbamoyl]-heptanoylamino}-1-carboxy-pentyl)-ureido]-pentanedioic acid (L3).
Compound L3 was prepared by reacting compound 9 35 with compound 6 similarly as described above for L1. HPLC purification was done by using 75/25 water (0.1% TFA)/CH 3 CN (0.1% TFA) as mobile phase, flow rate 2 mL/min, R t ) 8 min. 
2-[3-(1-Carboxy-5-{7-[6-(carboxymethyl-pyridin-2-ylmethylamino)-hexylcarbamoyl]-heptanoylamino}-pentyl)-ureido]-pentanedioic acid (L4).
Compound 10 was prepared following a published procedure. 36 Compound 11 was prepared as follows: to a solution of compound 10 (0.517 g, 1.7 mmol) in 10 mL of CH 2 Cl 2 was added a solution of glyoxylic acid monohydrate (1.55 g, 1.68 mmol in 1 mL of MeOH containing activated molecular sieves) and was stirred for 30 min. Sodium triacetoxyborohydride (0.712 + . To a solution of 12 (0.052 g, 0.11 mmol in 7 mL CH 2 Cl 2 ) was added 5 (0.1 g, 0.11 mmol), followed by NEt 3 (0.2 mL, 1.4 mmol). The reaction mixture was stirred at room temperature for 5 h and then concentrated under reduced pressure. Product isolation (EtOAc, water, NaCl, Na 2 SO 4 ) followed by flash chromatography (50/50 MeOH/CH 2 Cl 2 ) afforded pure compound the 4-methoxybenzyl ester of L5 in 51% (0.060 g, 0.056 mmol) yield. Cleavage of the PMB groups by stirring for 2 h in 1/1 TFA/CH 2 Cl 2 followed by removal of solvent gave a solid residue. The residue was dissolved in 7 mL water, washed with 3 × 10 mL CH 2 Cl 2 and the water layer concentrated under vacuum to provide crude L5. The compound was further purified by HPLC with 80/20 water (0.1% TFA)/CH 3 CN (0.1% TFA) solution as the mobile phase. The flow rate was 3 mL/min, R t ) 8 min 
2-{3-[5-(Bis-pyridin-2-ylmethyl-amino)-1-carboxy-pentyl]-ureido}-pentanedioic acid (L6).
To a solution of pyridine-2-aldehyde (50 mg, 0.44 mmol in 4 mL CH 2 Cl 2 ) was added a solution of 1 (100 mg, 0.147 mmol in 4 mL CH 2 Cl 2 ). This was stirred at ambient temperature for 2 h. The reaction mixture was cooled to 0°C, and sodium triacetoxyborohydride (93 mg, 0.44 mmol) was then added with stirring for an additional 3 h while warming to ambient temperature. Product isolation (CH 2 Cl 2 , water, NaCl, Na 2 SO 4 ) followed by flash chromatography (10/90 MeOH/CH 2 Cl 2 ) afforded a colorless solid as the tri-PMB ester of L6. Removal of the PMB groups was effected by dissolving in 5 mL of 50/50 TFA/CH 2 Cl 2 and was stirred at room temperature for 2 h. The resulting solution was concentrated to provide a colorless solid. The solid was dissolved in 3 mL water and washed with 5 × 5 mL CH 2 All rhenium compounds were synthesized as for ReL1, for which a detailed example is provided below.
Tricarbonyl ( 53 (m, 2H), 3.35 (t, J ) Fluorescence Spectra. Fluorescence spectra were recorded using a Varian Cary Eclipse fluorescence spectrophotometer using with 321 nm excitation from a Xenon arc lamp. Compound ReL2 was dissolved in ethylene glycol. Measurements were performed under air or after argon purging of the solution. Lifetime measurements were performed using a model D2, ISS, Inc. frequency domain spectrofluorimeter. The excitation wavelength was 370 nm from the UV LED. The fluorescence intensity data were collected through a bandpass filter in the spectral region 540-600 nm. Luminescence quantum yields were measured by the optical dilute method 57 using an aerated aqueous solution of [Ru(bpy) 3 ]Cl 2 (φ ) 0.028, excitation wavelength at 455 nm) 58 as the standard solution. NAALADase Assay. NAAG hydrolysis was performed essentially as described previously. 46, 47 In short, LNCaP cell extracts were prepared by sonication in NAALADase buffer [50 mM Tris (pH 7.4) and 0.5% Triton X-100]. Cell lysates were incubated with or without inhibitor at 37°C for 10 min. Following the incubation, the radiolabeled substrate N-acetyl-L-aspartyl-L- (3,4- 3 H)glutamate (NEN Life Science Products, Boston, MA) was added to a final concentration of 30 nM at 37°C for 10-15 min. The reaction was stopped by the addition of an equal volume of ice-cold 100 mM sodium phosphate and 2 mM EDTA. Products were partitioned by AG 1-X8 formate resin (Bio-Rad Laboratories) anion exchange chromatography, eluted with 1 M sodium formate, and quantified by liquid scintillation counting. Inhibition curves were determined using semilog plots and IC 50 values determined at the concentration at which enzyme activity was inhibited by 50%. Assays were performed in triplicate with the entire inhibition study being repeated at least once to confirm affinity and mode of inhibition. Data were collected during linear phase of hydrolysis (i.e., <20% cleavage of total substrate). Enzyme inhibitory constants (K i values) were generated using the Cheng-Prusoff conversion.
59
Cell Culture and Ex Vivo Biodistribution. PSMA+ PC3 PIP cells (human metastatic [bone] prostate carcinoma) engineered to express PSMA stably and PSMA-PC3 flu cells were generously provided by Warren Heston (Cleveland Clinic). Cells were cultured in T175 flasks using RPMI 1640 medium (Sigma) supplemented with 10% FBS and Penicillin/Streptomycin (100 U/mL/100 µg/ mL) at 37°C in 5% CO 2 in air. When a sufficient number of cells were present in culture, the cells were trypsinized and formulated in sterile Hanks buffered saline solution (Sigma, HBSS) and counted using a hemocytometer and trypan blue dye to confirm cell viability. Typically, 2-5 × 10 6 cells were injected subcutaneously such that PC3 PIP cells were injected behind the left shoulder and PC3 flu cells were injected behind the right shoulder of male severecombined immunodeficient mice (SCID). All in vivo experimental procedures were undertaken in compliance with United States laws governing animal experimentation and were approved by the Johns Hopkins University Institutional Animal Care and Use Committee. Mice were used when the tumors reached 3-7 mm in diameter for either ex vivo biodistribution studies or in vivo SPECT-CT.
The xenograft-bearing mice (17-20 g) were injected via the tail vein with 3.70 MBq (100 µCi) of [
99m Tc]L1-L4 in 200 µL of saline. Blood was collected immediately after sacrifice (cervical dislocation) by cardiac puncture and heart, lung, liver, stomach, pancreas, spleen, white fat, kidney, muscle, small intestine, large intestine, urinary bladder, and tumor xenografts were harvested, weighed, and counted in an automated gamma counter (LKB Wallace 1282 Compugamma CS Universal Gamma Counter). Animals were sacrificed at 30, 60, 120, and 300 min postinjection (n ) 4 per time point). Tissue radiopharmaceutical uptake values were calculated as percent injected dose per gram (% ID/g) as compared with a 1:10 diluted standard dose. The urinary bladder was emptied and water washed and then dried prior to weighing and counting.
SPECT-CT Imaging of PC3 PIP and PC3 flu Xenografts. Compounds L1-L4 were studied with imaging. Xenograft models were generated as described above. Mice were anesthetized using 1% isoflurane gas in oxygen flowing at 0.6 L/min prior to and during radiopharmaceutical injection. Mice were injected via the tail vein with approximately 480 µCi (17.76 MBq) of either L1, L2, L3, or L4 formulated in 200 µL of PBS, pH 7. Allowing for 15 min of radiopharmaceutical uptake, anesthetized mice were placed on the scanner gantry and secured with medical tape while the anesthetic flow was increased to 0.8 L/min. Body temperature of the mice was maintained by covering them with several layers of Chux disposable pads in addition to keeping them illuminated with a dissection lamp during scanning. A Gamma Medica (Northridge, CA) X-SPECT scanner equipped with two opposing low-energy 0.5 mm aperature pinholes and tunable CT was used for all scans. Mice were scanned over 180°in 5.5°, 30 s increments. A CT scan was performed prior to scintigraphy for both anatomical coregistration and attenuation correction. Data were reconstructed and fused using commercial software from the vendor (Gamma Medica), which includes a 2D-OSEM algorithm.
In Vivo Binding Specificity (Blocking) Study. Metabolite Studies. Male CD-1 mice (Charles River Laboratories) were injected with 15 µCi (555 kBq) of [
99m Tc]L1 in saline via the tail vein. Mice were sacrificed at either 30 min or 1 h postinjection by cervical dislocation and their blood and selected organs were removed. Blood samples were withdrawn using heparinized syringes, and tissues were placed on ice prior to manual homogenization in PBS, pH 7.4. Plasma and tissue homogenates in PBS were centrifuged for 2 min at 13000g at ambient temperature. A portion of the supernatant was diluted to 4 mL in 8 M urea containing 50 mg citric acid. Urine samples were added directly to 4 mL of the acidified urea solution. Samples then underwent separation by HPLC as previously described. 60 Briefly, the 4 mL sample in 8 M acidified urea was passed through a capture column (Strata-X, 19 mm × 4.4 mm, Phenomenex, Torrance, CA) at 2 mL/min followed by 1% acetonitrile in water to wash plasma proteins from the column. The effluent from the capture column, containing only highly polar components, flowed through a dual BGO detector (Bioscan, Washington, DC) operating in the diode mode. The solvent was then switched to 30% acetonitrile:50 mM phosphate buffer at pH 2.4 (2 mL/min) for elution of the radiolabeled components previously bound to the capture column onto the analytical column (Synergi Polar-RP 250 mm × 4.6 mm 10 µm particle size Phenomenex).
In Vitro Fluorescence Microscopy of ReL2 in PC3 PIP and PC3 flu Cells. Compound L2, when bound to the [Re(I)(CO) 3 ] + core, was hypothesized to be fluorescent as the corresponding bisquinoline chelator is known to have fluorescent properties. 30, 39, 40, 61 Following fresh preparation of ReL2, 10000 PC3 PIP and PC3 flu cells were seeded separately into each of four wells of a LaboratoryTek II 8-well chamber slide (Fisher Scientific). The cells were cultured as described above and were allowed to attach to the bottom of the wells overnight at 37°C in 5% CO 2 in air. Serially diluted aliquots of ReL2 were added to the media in six of the wells such that wells contained 500 nM, 250 nM or 125 nM ReL2 with two remaining free of fluorophore. The cells were then returned to the incubator for one hour to enable binding. Each well was then carefully washed by removing the supernatant followed by addition of warm culture media for 30 s. The wash media was then removed and added to the contents of the well chambers. Dako Cytomation mounting medium was then applied and a glass coverslip was added. The mounting medium was allowed to dry at ambient temperature for 20 min prior to storage of the slide at 4°C overnight. The cells were then viewed using an Olympus BX61 fluorescence microscope equipped with a Semrock DAPI/FITC/ Texas Red triple filter cube. Excitation was at 494 nm with collection of emitted fluorescence at 628 nm.
